Development of an in vitro assay for detection of drug induced Resuscitation-promoting factor dependent mycobacteria by Loraine, J et al.
Development of an In Vitro Assay for Detection of Drug-Induced
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Tuberculosis is a major infectious disease that requires prolonged chemotherapy with a combination of four drugs. Here we
present data suggesting that treatment ofMycobacterium tuberculosis, the causative agent of tuberculosis, andMycobacterium
smegmatis, a model organism widely used for the screening of antituberculosis agents, with first-line drugs resulted in the gener-
ation of substantial populations that could be recovered only by the addition of a culture supernatant from growing mycobacte-
ria. These bacilli failed to grow in standard media, resulting in significant underestimation of the numbers of viable mycobacte-
ria in treated samples. We generatedM. smegmatis strains overexpressingM. tuberculosis resuscitation-promoting factors
(Rpfs) and demonstrated their application for the detection of Rpf-dependent mycobacteria generated after drug exposure. Our
data offer novel opportunities for validation of the sterilizing activity of antituberculosis agents.
Approximately one-third of the world’s population is latentlyinfected with Mycobacterium tuberculosis, the causative agent
of human tuberculosis (TB) (1). M. tuberculosis bacilli can adapt
to stressful conditions occurring at sites of host defense by
reducing their metabolic activity and adopting a dormant state,
often referred to as nonreplicating persistence (NRP) (2). Dor-
mancy, or NRP, enables mycobacteria to survive environmen-
tal stresses and reduces the initiation of the immune response
(3). Hence, dormancy can be defined as “a reversible state of
low metabolic activity in which cells can exist for extended
periods without division” (4).
Dormant bacilli, which are associated with latent infection, are
believed to be less susceptible to antimicrobial treatment than
actively growing bacilli due to physiological changes and therefore
are of clinical significance in the eradication of TB (5). Nonrepli-
cating M. tuberculosis bacilli generated in various in vitro models
were more tolerant to rifampin and isoniazid than actively grow-
ing bacilli. These systems include the Wayne hypoxia model (2),
starvation in phosphate buffer (6), a multiple-stress model (7), the
persistence of a streptomycin-dependent strain (8), and a “non-
culturability” model induced by potassium limitation (9). Thus,
investigation of drug action on NRP bacteria and the development
of in vitro models for the generation of such bacteria have been
considered important for successful drug discovery programs.
However, recent comparative studies on drug activities on NRP
mycobacteria in in vitro systems showed significant differences
(10). The presence of multiple mycobacterial populations with
various physiological characteristics in NRP models may contrib-
ute to variability in the killing activity of drugs. Furthermore, the
in vivo environment and exposure to stressful conditions may
spawn heterogeneous mycobacterial populations with distinct
cultivation requirements (11) and biochemical characteristics
(12). Of particular interest are so-called resuscitation-promoting
factor (Rpf)-dependent mycobacteria. Rpfs are a family of se-
creted peptidoglycan-remodeling enzymes, which are required for
the regrowth of dormant bacteria (13). Rpf-dependent mycobac-
teria can be generated in vitro (14, 15), but most importantly, they
are highly abundant in tuberculosis sputum (16) and can be re-
covered from infected lungs (11). Rpf-dependent M. tuberculosis
bacilli from sputum have been shown to be more tolerant to ri-
fampin (16), streptomycin, and isoniazid (17) than actively grow-
ing bacilli. Moreover, Hu and colleagues have recently demon-
strated that Rpf-dependent M. tuberculosis bacilli were present in
apparently sterile murine lungs in the Cornell model of latent
tuberculosis infection and that the abundance of these bacilli cor-
related with tuberculosis reactivation (18). These observations
suggest the necessity of monitoring the dynamics of Rpf-depen-
dent M. tuberculosis during infection and treatment in order to
predict chemotherapy outcomes for TB patients. Thus, there is
strong demand for the development of simple assays to detect
Rpf-dependent M. tuberculosis in clinical and experimental sam-
ples. The major challenge in Rpf dependency assays is posed by the
high instability and unreliable activity of recombinant Rpf (19).
Culture supernatants (SN) obtained from growing M. tuberculosis
have been used as an alternative source for the detection of Rpf-
dependent mycobacteria (16, 20, 21); however, this experimental
setup is highly laborious and requires additional controls, pre-
venting large-scale clinical studies and high-throughput drug test-
ing. Moreover, other factors released into the culture supernatants
of growing bacteria may contribute to the resuscitation of non-
platable (NP) bacteria and complicate the interpretation of re-
sults.
In this study, we demonstrate that treatment of mycobacterial
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cultures with first-line drugs results in the generation of bacteria
that could be grown only in media supplemented with the culture
supernatant. We have generatedMycobacterium smegmatis strains
overexpressing M. tuberculosis Rpfs and have shown that these
strains can be used for the detection of Rpf-dependent cells that
arose after exposure to drugs. Our simple in vitro system can be
used for assessing the efficacy of drugs and their propensity to
generate Rpf-dependent mycobacteria.
MATERIALS AND METHODS
Bacteria and media.M. smegmatis mc2155 or M. tuberculosis H37Rv was
grown at 37°C. Bacteria were cultivated either in 7H9 Middlebrook me-
dium (Becton, Dickinson and Company Ltd., Oxford, United Kingdom)
supplemented with 0.2% (vol/vol) glycerol, 10% (vol/vol) oleic acid-al-
bumin-dextrose-catalase (OADC), and 0.05% (wt/vol) Tween 80 or in
Sauton’s medium, unless otherwise stated. In some experiments, the
OADC supplement was replaced with ADC; no significant difference in
mycobacterial growth was found. Liquid cultures were shaken either at
100 rpm (M. tuberculosis) or at 200 rpm (M. smegmatis). For CFU assess-
ment, mycobacteria were plated onto 7H10 Middlebrook (Becton, Dick-
inson and Company Ltd., Oxford, United Kingdom) agar. For main-
tenance of the pMind plasmid, kanamycin was added to a final
concentration of 50 g/ml; tetracycline (20 ng/ml) was added for in-
duction of the expression of rpf genes.
Assessment of viable counts. CFU counts, using a standard liquid
droplet method with serially diluted bacterial cultures, were performed in
triplicate. Sealed agar plates were incubated at 37°C for as long as 1 week
(M. smegmatis) or as long as 6 weeks (M. tuberculosis). Most probable
number (MPN) counts were performed as described previously (16).
Briefly, mycobacteria were serially diluted in 96-well (M. smegmatis) or
48-well (M. tuberculosis) microtiter plates containing growth broth with
or without a culture supernatant prepared from actively growing M. tu-
berculosis cultures (16). For M. tuberculosis, 50 l of mycobacteria was
inoculated in 450 l of 7H9 medium supplemented with 10% (vol/vol)
OADC and 0.05% (vol/vol) Tween or in 450 l of medium diluted with a
culture supernatant (50% [vol/vol]). ForM. smegmatis experiments, 20l
of a bacterial suspension was inoculated in 180 l of Sauton’s medium
with or without a culture supernatant. Four wells were used for each
dilution and each medium. Plates were incubated for 2 weeks (M. smeg-
matis) or 12 weeks (M. tuberculosis) statically at 37°C before the number of
positive wells was recorded and MPN calculated as described previously
(16). Each sample was analyzed in triplicate; duplicate biological replicas
were used per assay, and each independent assay was performed at least
twice. The following terminology was introduced to describe mycobacte-
ria in different physiological states: platable (CFU-producing) bacteria
formed on solid media; “nonplatable” (NP) forms could grow only in
liquid media; SN-dependent mycobacteria could be grown only in the
presence of an Rpf-containing culture supernatant; Rpf-dependent my-
cobacteria required Rpf for growth (17). NP, SN-dependent, or Rpf-de-
pendent mycobacteria were quantified in an MPN assay, and the resusci-
tation potential of mycobacterial populations was expressed as the
resuscitation index (RI), calculated as log10(MPN) log10(CFU).
Growth studies. Growth studies were carried out in supplemented
7H9 medium using an automated Bioscreen C MBR plate reader (Thermo
Fisher Scientific) as described previously (22, 23). Cultures from the late-
logarithmic phase were inoculated into supplemented 7H9 medium con-
taining 50 g/ml kanamycin and 20 ng/ml tetracycline to a final optical
density (OD) of 0.1. Numbers of inoculated bacteria were confirmed by
CFU counts. Plates were then incubated at 37°C with continuous shaking,
and OD measurements were taken automatically every 2 h at 600 nm. Ten
replicas were used per sample, and each experiment was performed a
minimum of three times.
The growth rate (per hour) was calculated by plotting a log scale graph
of linear growth and generating an exponential line showing the equation
of the line, the gradient (slope) of which is equal to the growth rate. All
trend lines had an R2 value of at least 0.99. The apparent lag phase was
measured as the time taken for the first OD doubling (determined as an
OD of 0.2). The final OD at 600 nm (OD600) corresponded to the highest
optical density reached by cultures during growth.
Exposure to antimicrobials. M. tuberculosis from the logarithmic-
growth stage was inoculated into 10 ml of supplemented 7H9 medium
containing an antimicrobial agent and was incubated at 37°C with shaking
for 3 days. The initial inocula in all experiments were (4  1.5)  107
CFU/ml. After centrifugation at 4,000 g, pellets were washed once with
7H9 medium, resuspended in 1 ml of supplemented 7H9 medium, and
used for the estimation of CFU, MPN, and MNP counts in the presence of
culture supernatant (MPN_SN). Antimicrobial concentrations (in mi-
crograms per milliliter) were as follows: streptomycin, 20; isoniazid, 10;
ethambutol, 20; rifampin, 5. The exposure of M. tuberculosis to these drug
concentrations resulted in marked decreases in CFU counts (2 log10).
M. smegmatis was inoculated from a single colony into 5 ml of LB
supplemented with 0.05% (wt/vol) Tween 80 and was grown at 37°C with
shaking at 200 rpm for 24 h. The culture (1 ml) was then centrifuged for 10
min at 14,000  g and was resuspended in 1 ml of Sauton’s medium
supplemented with one of the following drugs (with concentrations given
in micrograms per milliliter): amikacin (100), meropenem (50), rifampin
(5, 25, or 100), ethambutol (20), isoniazid (1, 10, or 100), or streptomycin
(10 or 20). Samples were incubated at 37°C with shaking for 24 h. After
washing with Sauton’s medium, the treated cells were resuspended in 1 ml
of Sauton’s medium and were used for CFU, MPN, and MPN_SN assays.
When strains containing pMind plasmids were assessed, kanamycin was
added at a final concentration of 50 g/ml at all stages of the experiment.
Plates were incubated for 2 weeks statically at 37°C before the number of
positive wells was recorded. Each sample was analyzed in triplicate; dupli-
cate biological replicas were used per assay; and each independent assay
was performed at least twice
Generation of Rpf-overexpressing strains. The rpfABCDE genes
were amplified from the M. tuberculosis genome by PCR using the gene-
specific primers listed in Table S1 in the supplemental material. The PCR
products were cloned into the BamHI and MluI (24) sites of the pMind
plasmid or pMind-6His-Myc (23), and the constructs were sequenced
by GATC Biotech (Germany) before electroporation into M. smegmatis.
The transformants were selected by incorporating kanamycin at a final
concentration of 50 g/ml into the growth medium. The identities of the
resultant strains were confirmed using colony PCR and the pMind-spe-
cific primers MindF and MindR. A control M. smegmatis strain contained
an empty pMind plasmid. rpf expression was induced by the addition of
20 ng/ml tetracycline. The plasmids and strains generated in this study are
shown in Table 1. The MICs of rifampin and isoniazid for pMind and the
RpfD-overexpressing strain were determined by the microdilution
method as described previously (23).
RNA extraction and qRT-PCR. RNA was extracted from 10 ml of
mid-log-phase mycobacterial cultures using a previously described
TRIzol method (25). To remove DNA contamination, RNA samples were
cleaned using the Turbo DNA-free kit (Invitrogen). cDNA synthesis, us-
ing the commercially available SuperScript II reverse transcriptase kit (In-
vitrogen), was performed according to the manufacturer’s instructions.
Quantitative real-time PCR (qRT-PCR) experiments were carried out in a
Corbett Rotor Gene 6000 real-time thermocycler. Absolute qPCR SYBR
green mix (ABgene) and gene-specific primers were used as described
previously (26). The level of expression of each individual M. tuberculosis
rpf gene was normalized to that of 16S rRNA (26). Amplification efficien-
cies were automatically calculated using Rotor Gene 6000 series software.
Melting curves were used to confirm the specificity of the qPCR product.
Detection of Rpf in culture supernatants. Enzyme-linked immu-
nosorbent assays (ELISAs) were carried out using a method adapted from
previously published work (15). Briefly, supernatants (10 ml) were ob-
tained from logarithmic-phase cultures grown in Sauton’s medium. After
centrifugation and filtration, supernatants were concentrated by freeze-
drying. Dried samples were resuspended in 1 ml phosphate-buffered sa-
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line (PBS). ELISA was performed in 96-well plates with 100 l of a con-
centrated culture supernatant. Primary monoclonal anti-polyhistidine
(Sigma-Aldrich) or polyclonal anti-Rpf (13) antibodies and alkaline
phosphatase-conjugated secondary anti-mouse or anti-sheep antibodies
(respectively) were used at dilutions of 1:3,000 and 1:10,000, respectively.
A p-nitrophenyl phosphate substrate (Sigma-Aldrich) was used for the
detection of alkaline phosphatase activity. The reaction was measured
spectrophotometrically at 405 nm, using a Model 680 microplate reader
(Bio-Rad).
RESULTS
Drug treatment induces culture supernatantdependency inmy-
cobacteria. Previous studies have shown that antimicrobial treat-
ment of mycobacteria can result in the generation of metabolically
distinct forms (12). Thus, the presence of NP mycobacteria in the
drug-treated population was investigated. M. tuberculosis cultures
were treated with isoniazid, rifampin, ethambutol, or streptomy-
cin for 3 days, and viable counts of surviving cells were determined
using CFU and MPN counts with or without the addition of Rpf-
containing culture supernatants (Rpf-SN) (see Fig. S1 in the sup-
plemental material). As shown in Fig. 1A and Fig. S1, no signifi-
cant resuscitation was observed in 7H9 medium after treatment
with any of these drugs. However, the addition of Rpf-SN caused
significant increases in viable counts after treatment with etham-
butol, isoniazid, or rifampin. Interestingly, streptomycin was very
efficient at eliminating mycobacteria and did not result in the
generation of resuscitatable mycobacteria. Treatment of myco-
bacteria with 10 or 20 g/ml of streptomycin resulted in similar
outcomes (data not shown). Further incubation of mycobacteria
with drugs led to reductions in resuscitation indices for isoniazid
and ethambutol but not for rifampin (Fig. 1B; also Fig. S1), show-
ing that cell wall-targeting antimicrobials induce temporary SN
dependency.
Next, the propensity of drugs to induce SN dependency was
investigated using M. smegmatis cultures (Fig. 1C and D; see also
Fig. S2 in the supplemental material). While streptomycin and
amikacin did not induce SN dependency, meropenem, ethambu-
tol, isoniazid, and rifampin generated high numbers of mycobac-
teria that could be resuscitated only in the presence of a culture
supernatant. However, as with M. tuberculosis culture, further in-
cubation with drugs reduced the numbers of resuscitating myco-
bacteria in samples treated with meropenem or isoniazid (Fig.
1D). These data indicate that certain drugs can result in the gen-
eration of NP mycobacteria, which can be detected by the ap-
plication of a liquid culture supplemented with Rpf-containing
culture supernatants. To simplify this assay and prove the resus-
citating effect of Rpfs, we generated M. smegmatis strains that
artificially overproduce M. tuberculosis Rpfs and validated their
usefulness for the detection of Rpf-dependent mycobacteria in-
duced by drug treatment.
Generation and validation of strains overexpressing rpf
genes. Each of the five M. tuberculosis rpf genes (rpfABCDE) was
TABLE 1 Strains generated in this study
Plasmid name Strain Insert size (bp)a Primers Description
pMind::rpfA RpfA overexpression 1,224 RpfAF and RpfAR M. tuberculosis rpfA gene cloned into pMind
pMind::rpfB RpfB overexpression 1,089 RpfBF and RpfBR M. tuberculosis rpfB gene cloned into pMind
pMind::rpfC RpfC overexpression 531 RpfCF and RpfCR M. tuberculosis rpfC gene cloned into pMind
pMind::rpfD RpfD overexpression 465 RpfDF and RpfDR M. tuberculosis rpfD gene cloned into pMind
pMind::rpfE RpfE overexpression 519 RpfEF and RpfER M. tuberculosis rpfE gene cloned into pMind
pMind::rpf Rpf overexpression 696 RpfF and RpfR M. luteus rpf gene cloned into pMind
pMind MIND N/A N/A Empty plasmid control
a N/A, not applicable.
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FIG 1 Antimicrobial treatment induces SN dependency in mycobacteria. M.
tuberculosis (A and B) or M. smegmatis (C and D) was treated with antimicro-
bial agents as described in Materials and Methods. M. tuberculosis was exposed
to drugs for 3 (A) or 7 (B) days. M. smegmatis was treated for 24 h (C) or 48 h
(D). The resuscitation index was calculated as log10(MPN) log10(CFU). Str,
streptomycin; Rif, rifampin; Emb, ethambutol; INH, isoniazid; Mer, mero-
penem; Ami, amikacin. Average values for two independent experiments with
three biological replicates are shown; error bars indicate standard deviations.
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cloned into the pMind or pMind-6His-Myc plasmid, and the
level of rpf expression was assessed using qRT-PCR. In separate
experiments, the amounts of Rpfs released into culture superna-
tants were determined by ELISAs using anti-polyhistidine or anti-
Rpf (13) antibodies. As can be observed in Fig. 2A, the M. tuber-
culosis rpf genes were expressed from the pMind plasmid at
different levels: rpfDwas expressed at the highest level, followed by
rpfE, rpfC, rpfA, and rpfB. Measurement of Rpfs in culture super-
natants using polyclonal anti-polyhistidine antibodies confirmed
the increases in Rpf levels in the overexpressing strains: those
overexpressing RpfA and RpfE showed the greatest absorbance,
followed by those with RpfB and RpfD (Fig. 2B). Similar results
were obtained with anti-Rpf antibodies (data not shown). The
apparent discrepancy between the qRT-PCR data and the ELISA
results could be explained by the attachment of Rpfs to the cell
wall, as demonstrated previously (27).
Next, the effects of M. tuberculosis rpf overexpression on the
growth of M. smegmatis were examined. Growth experiments
were carried out in supplemented 7H9 medium, and growth pa-
rameters were calculated (Table 2). The overexpression of any M.
tuberculosis rpf gene resulted in a slight but statistically significant
increase in the final OD over that for the control strain (P,0.05
by the t test). Differences in the growth rate were also observed;
RpfA, RpfB, and RpfC led to increases in the growth rate, while
RpfE led to a slightly reduced growth rate. RpfD and Micrococcus
luteus Rpf led to growth rates comparable to that of the control
strain. Examination of the apparent lag phase revealed a slight
reduction in strains overexpressing rpfC or rpfD and a smaller
reduction in strains overexpressing rpfE or M. luteus rpf (Table 2).
Overexpression of M. tuberculosis Rpfs also altered the growth of
M. smegmatis in Sauton’s broth (see Fig. S3 in the supplemental
material).
Rpfs have previously been implicated in the resuscitation of NP
M. tuberculosis cells and have shown cross-species reactivity, in-
cluding reactivity in M. smegmatis and Mycobacterium bovis BCG
(13, 14). The resuscitation abilities of the individual M. tuberculo-
sis Rpfs in the M. smegmatis Rpf-overexpressing strains were es-
tablished in a control system prior to assessment of the front-line
antituberculosis drugs. To determine the resuscitation capabilities
of rpf-overproducing strains, we used a well-established M. smeg-
matis NP model (15). This assay uses potassium-limiting condi-
tions to generate NP cells that are unable to grow in standard
media and can be resuscitated only by the addition of SN or re-
combinant Rpf. All five strains overexpressingM. tuberculosisRpfs
produced no colonies on agar but resuscitated in liquid medium.
In agreement with the data published previously, M. smegmatis
overexpressing M. luteus Rpf (15) was also able to grow in liquid
culture, while the empty-plasmid control failed to resuscitate (Fig.
3). RpfA and RpfD had the greatest resuscitation capacity, as re-
flected by the highest resuscitation index values (4.7 and 5.3, re-
spectively), followed by RpfB, RpfC, and RpfE. Interestingly,
rpfD was the most overexpressed gene by qRT-PCR, while RpfA
was the most abundant Rpf protein detected in culture super-
natants by ELISA. These results indicated that Rpf-overex-
pressing strains could be used for the detection of Rpf-depen-
dent mycobacteria.
Rpf overexpression rescues nonculturable mycobacteria
generated by treatment with front-line drugs. To investigate the
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FIG 2 Confirmation of M. tuberculosis rpf gene overexpression and Rpf pro-
duction in M. smegmatis strains. (A) Expression of rpfA through rpfE as a
percentage of 16S rRNA expression. (B) Detection of RpfA, RpfB, RpfD, and
RpfE in M. smegmatis culture supernatants by ELISA with monoclonal anti-
polyhistidine antibodies. A recombinant His-tagged form of RpfB (designated
Rpf) was used as a positive control. RpfC production was not assessed.
TABLE 2 Comparative analysis of growth parameters of strains
overexpressing rpf genes
Strain or description Apparent lag phase (h)a
Final
ODb
Growth rate
(h1)b,c
MIND 20 0.66 0.71 0.19
RpfA overexpression 20 0.88 0.82* 0.22*
RpfB overexpression 20 0.71 0.82* 0.21*
RpfC overexpression 18 0.88 0.81* 0.20*
RpfD overexpression 18 0.66 0.81* 0.19
RpfE overexpression 19 0.5 0.81* 0.18*
M. luteus Rpf overexpression 19 0.53 0.84* 0.19
a Values are means standard deviations.
b Asterisks indicate values significantly different from that for the control strain, MIND
(P,0.05 by the t test).
c Growth parameters were calculated as described in Materials and Methods.
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FIG 3 Overexpressed M. tuberculosis rpf genes resuscitate nonplatable M.
smegmatis. NP mycobacteria were generated in potassium-limited medium.
Resuscitation was carried out in Sauton’s medium supplemented with 50
g/ml of kanamycin and 20 ng/ml of tetracycline. The resuscitation index was
calculated as log10(MPN) log10(CFU). Average values for three independent
experiments are shown; error bars indicate standard deviations. The limit of
detection was 0.2. The limit-of-detection value is shown for the MIND strain.
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abilities of individual Rpfs to resuscitate drug-treated mycobacte-
ria, M. smegmatis Rpf-overexpressing strains and the control
strain MIND were treated with rifampin, ethambutol, or mero-
penem, and the numbers of surviving bacteria were determined by
CFU and MPN counts. CFU counts in all treated populations
decreased by 2 orders of magnitude from those with the initial
inocula (see Fig. S4 in the supplemental material). Figure 4A
shows resuscitation indices calculated for rifampin-, mero-
penem-, and ethambutol-treated samples. The highest values
were obtained for meropenem-treated samples, confirming the
data for M. smegmatis presented in Fig. 1C. Rifampin and etham-
butol treatment also led to the generation of Rpf-dependent my-
cobacteria. On the other hand, CFU counts for streptomycin-
treated samples were below the limit of detection, corresponding
to 25 cells/ml, and no resuscitation was observed for any of the Rpf
overexpression strains, suggesting that this drug treatment does
not induce Rpf dependency (data not shown). Reducing the strep-
tomycin concentration to 10g/ml did not increase viable counts.
This apparently increased sensitivity of Rpf overexpression strains
to streptomycin may be caused by the presence of the plasmids or
the administration of kanamycin for their maintenance, or both.
Among the strains overexpressing different Rpfs, the RpfD-
overexpressing strain showed consistently higher resuscitation
than the others, while the RpfE-overexpressing strain showed the
lowest resuscitation potential. In accordance with previously pub-
lished data, the empty-plasmid strain did not resuscitate in liquid
medium, while the positive-control strain overexpressing M. lu-
teus Rpf showed high resuscitation potential (15).
We next investigated how different concentrations of drug in-
fluence the generation of Rpf-dependent mycobacteria. We
treated the pMind control strain and the RpfD-overexpressing
strain with three different concentrations of isoniazid (1, 10, and
100 g/ml). According to our data, the isoniazid MICs for the
pMind and RpfD-overexpressing strains were identical (5g/ml).
As Fig. S5 in the supplemental material shows, at a concentration
of 1g/ml, isoniazid did not influence the viability of M. smegma-
tis and did not result in the generation of RpfD-dependent myco-
bacteria, while high numbers of RpfD-dependent mycobacteria
arose after exposure to 10 or 100 g/ml of isoniazid (Fig. 4B). A
similar pattern was obtained with rifampin-treated mycobacteria.
The rifampin MIC was 16 g/ml for both strains. At 5 g/ml
rifampin, mycobacteria were able to grow without a loss of viabil-
ity and did not produce RpfD-dependent forms (Fig. 4C; also Fig.
S5). Treatment with 25 g/ml rifampin stopped the growth of
mycobacteria but did not stimulate RpfD dependency; exposure
to 100 g/ml of rifampin resulted in the accumulation of RpfD-
dependent M. smegmatis cells. An increase in the drug exposure
time to 48 h did not significantly change the viable counts (data
not shown); we noted outgrowth of mycobacteria if the time of
incubation was extended beyond 72 h. The observed outgrowth of
mycobacteria could be caused by the multiplication of drug-resis-
tant mutants or the degradation of drugs.
DISCUSSION
Tuberculosis is a worldwide health threat, and recent global efforts
have been directed to the development of novel agents to eradicate
M. tuberculosis and especially its nonreplicating forms, which are
believed to be responsible for prolonged treatment and disease
relapse. Populations of nonreplicating, Rpf-dependent, and SN-
dependent cells were recently identified in patient sputum sam-
ples and were apparently enriched in treated samples (16, 28),
leading to our hypothesis that antituberculosis drugs may induce
Rpf dependency. Accordingly, we investigated whether mycobac-
teria from growing cultures could become NP or SN dependent
after exposure to antimicrobial agents. In our experiments, we did
not detect substantial numbers of NP mycobacteria that could be
regrown in liquid medium (Fig. 1). However, mycobacterial pop-
ulations treated with either rifampin, ethambutol, isoniazid, or
meropenem did indeed develop SN dependency. This phenome-
non was observed forM. tuberculosis andM. smegmatis, suggesting
that it is not associated with slow-growing mycobacteria. The
numbers of SN-dependent mycobacteria obtained after treatment
with cell wall-targeting drugs decreased after extended incubation
(Fig. 1B and D), though rifampin-induced SN-dependent popu-
lations remained stable even during prolonged treatment (Fig. 1B
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FIG 4 Use of strains overexpressing rpf genes for the detection of Rpf-depen-
dent mycobacteria induced by treatment with antituberculosis drugs. Strains
were treated with ethambutol (EMB), meropenem (MER), or rifampin (RIF)
(A), isoniazid (B), or rifampin (C). The resuscitation index was calculated as
log10(MPN)  log10(CFU). Average values for three independent experi-
ments are shown; error bars indicate standard deviations. The limit of
detection was 0.2.
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and D). We have shown previously that the resuscitation effect of
culture supernatant was caused mainly by Rpf proteins (11, 14,
16). Therefore, we hypothesized that artificial overexpression of
Rpf in treated mycobacteria might induce their resuscitation, and
consequently, we developed a model system using M. smegmatis
strains overexpressing M. tuberculosis Rpfs.
The expression of each M. tuberculosis rpf gene was confirmed
at the RNA level by qRT-PCR (Fig. 2A); the release of Rpf proteins
was confirmed by ELISA (Fig. 2B). The Rpf-overexpressing strains
showed a growth advantage in 7H9 medium (Table 2) and in
Sauton’s broth (Fig. S3 in the supplemental material); they were
also able to resuscitate in an NP model (Fig. 3), suggesting their
potential utility for the investigation of drug-induced Rpf-depen-
dent mycobacteria. Our results indicate that overexpressed Rpfs
resuscitate Rpf-dependent M. smegmatis (Fig. 4). Moreover, the
resuscitation effects of overexpressed Rpfs were very similar to
those of culture supernatant (Fig. 1B).
While the biological significance of these Rpf-dependent pop-
ulations awaits further evaluation, our findings indicate that the
bactericidal actions of meropenem, isoniazid, ethambutol, and
rifampin may have been overestimated. Interestingly, neither
streptomycin nor amikacin induced Rpf-dependent mycobacteria
in any of our assays, suggesting that aminoglycosides are potent
drugs for the prevention of Rpf dependency in mycobacteria. The
Rpf proteins are the enzymes involved in the remodeling, biosyn-
thesis, and (potentially) repair of bacterial cell walls. Any environ-
mental insult, including drug treatment, leading to alteration or
damage of the cell wall may put bacteria in a situation where the
role of cell wall-modifying enzymes, such as Rpfs, becomes vital.
Thus, the data presented indicate that drug-induced Rpf depen-
dency may be associated with inhibition or damage of cell wall
biosynthesis but not with a shutdown of protein biosynthesis. We
also cannot exclude the possibility that drug treatment helps to
reveal some “preexisting” Rpf-dependent populations by elimi-
nating most of the platable bacteria from actively growing cul-
tures. The phenomenon of “persisters” has long been recognized,
and persisters are believed to arise stochastically in growing cul-
tures (29).
We have demonstrated recently that SN-dependent mycobac-
teria from sputum are more tolerant to isoniazid and streptomy-
cin than actively growing mycobacteria (17). This potentially
means that Rpf-dependentM. tuberculosis bacilli generated in vivo
are more resistant to protein biosynthesis inhibition than bacteria
from actively growing cultures and that the enrichment of SN- or
Rpf-dependent M. tuberculosis bacilli in samples from treated
patients is due to their higher tolerance to drugs. Interestingly,
treatment of growing cultures with ethambutol induced SN de-
pendency both in M. tuberculosis and in M. smegmatis; however,
SN-dependent mycobacteria from sputum did not show higher
tolerance to this drug than actively growing mycobacteria (17),
suggesting the complex nature of the SN dependency phenome-
non. Nevertheless, it is possible that some Rpf-dependent M. tu-
berculosis bacilli isolated from posttreatment samples resulted
from drug exposure. Thus, ourM. smegmatismodel system can be
used for the detection of drugs with a high propensity to induce
Rpf dependency. Our assay using Rpf-overexpressing strains in
the nonpathogenic bacterium M. smegmatis has been shown to
accurately model the effects observed in M. tuberculosis. Drug re-
sistance in TB is on the rise, and current efforts are focused on
developing new antibiotics that will be effective against multi-
drug-resistant TB (MDR-TB) and extensively drug resistant TB
(XDR-TB). It is therefore worthwhile to investigate a simple in
vitro method for assessing the Rpf-dependent populations pro-
duced by antimicrobial treatments in order to help prevent resis-
tance in the future.
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